Medmix AG (XSWX:MEDX) ROCE % : -0.05% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Medmix AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medmix AG's annualized ROCE % for the quarter that ended in Dec. 2023 was -0.05%.

Medmix AG ROCE % Historical Data

The historical data trend for Medmix AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medmix AG ROCE % Chart

Medmix AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.28

2.92

7.86

2.20

1.56

Medmix AG Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					7.81	3.94	0.45	3.18	-0.05

Medmix AG ROCE % Calculation

Medmix AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	13	/	( ( (1105.9 - 271.1)	+	(1006.8 - 178.1) )	/ 2 )
	=	13	/	( (834.8	+	828.7)	/ 2 )
	=	13	/	831.75
	=	1.56 %

Medmix AG's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-0.4	/	( ( (971.6 - 147.6)	+	(1006.8 - 178.1) )	/ 2 )
	=	-0.4	/	( ( 824	+	828.7 )	/ 2 )
	=	-0.4	/	826.35
	=	-0.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Medmix AG (XSWX:MEDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medmix AG ROCE % Related Terms

Thank you for viewing the detailed overview of Medmix AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medmix AG (XSWX:MEDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Medmix AG (XSWX:MEDX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MDMXF:USA MEDXz:UK

Address

Dammstrasse 19, Baar, Zug, CHE, 6340

Website

https://www.medmix.swiss

Medmix AG delivers technologies in high-precision delivery devices and fluid mixing for applications. It is into two business areas Healthcare and Consumer & Industrial. The Healthcare business area is divided into the Dental, Drug Delivery and Surgery segments. The Consumer & Industrial business area operates through the Industry and Beauty segments. The majority of revenue is from Consumer & Industrial segment. In the Industry segment, dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways and aerospace), electronics assembly, infrastructure and DIY industries. Geographically, it operates in Europe the Middle East and Africa, the Americas and Asia-Pacific.